2seventy bio Inc. reports developments centered on Abecma, its FDA-approved CAR T cell therapy for multiple myeloma, and the U.S. collaboration with Bristol Myers Squibb. News commonly covers Abecma commercialization, regulatory and clinical updates, KarMMa study decisions, collaborative arrangement revenue, operating results, cash position, cost management, material agreements, capital-structure disclosures and governance matters.
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.46%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.62%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.9%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.3%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.3%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.31%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
FAQ
What is the current stock price of 2seventy bio (TSVT)?
2seventy bio (TSVT) last closed at $5.
What is the market cap of 2seventy bio (TSVT)?
The market cap of 2seventy bio (TSVT) is approximately $266.1M.